HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso

The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market.

By FiercePharma · Apr 23, 2026 · via FiercePharma
Merck amps up presence in HIV treatment market with FDA nod for novel combo pill Idvynso

Image: FiercePharma

Tags
pipelineformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
PipelineFierceBiotech ↗
Racing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person sy…
Apr 23, 2026
Moderna continues bird flu vax study, but limits work in the U.S.
PipelineSTAT News ↗
Moderna continues bird flu vax study, but limits work in the U.S.
Flu shot no longer mandated for U.S. troops, "healthy" snacks, and other news from Morning Rounds…
Apr 22, 2026
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
PipelineFierceBiotech ↗
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, R…
Apr 22, 2026